Forming a Medicines Pricing Policy for Low and Middle-income Countries (LMICs): the Case for Pakistan

Overview

Journal J Pharm Policy Pract

Date 2022 Feb 25

PMID 35209945

Authors

Zaheer-Ud-Din Babar

Affiliations

Soon will be listed here.

Abstract

Equitable access to medicines has played a vital role to improve patient health outcomes and reducing mortality globally. However, it is important to note that medicines pricing is a key determinant in promoting access to medicines. The studies and empirical data have shown that there are wide variations in prices across countries for the same brand of medicines. World Health Organisation (WHO) has provided guidelines to formulate country pharmaceutical pricing policies. However, little is known how these guidelines will be used in the country-specific setting. This commentary provides guiding principles and outlines the basis to form a medicines pricing policy in a low and middle-income country, Pakistan. It discusses the current medicines pricing policy and provides suggestions for future work. The suggested medicines pricing structure and lessons learned in this commentary can also be applied in other low-resource settings.

Citing Articles

Establishing links between drug registers and essential medicines lists.

Brhlikova P, Babar Z, Pollock A Bull World Health Organ. 2025; 103(1):37-42.

PMID: 39780996 PMC: 11704638. DOI: 10.2471/BLT.24.291512.

Effective Supply Chain Strategies in Addressing Demand and Supply Uncertainty: A Case Study of Ethiopian Pharmaceutical Supply Services.

Bilal A, Bititci U, Gedif Fenta T Pharmacy (Basel). 2024; 12(5).

PMID: 39311123 PMC: 11417768. DOI: 10.3390/pharmacy12050132.

Building an effective medicines optimisation model: a health system approach.

Babar Z Int J Clin Pharm. 2024; 46(5):1237-1242.

PMID: 38896393 DOI: 10.1007/s11096-024-01765-3.

Developing Nepal's medicines pricing policy: evidence synthesis and stakeholders' consultation.

Babar Z, Dulal S, Dhakal N, Upadhyaya M, Trap B J Pharm Policy Pract. 2024; 17(1):2346222.

PMID: 38690551 PMC: 11060005. DOI: 10.1080/20523211.2024.2346222.

Implementation of Medicines Pricing Policies in Ghana: The Interplay of Policy Content, Actors' Participation, and Context.

Koduah A, Baatiema L, Kretchy I, Agyepong I, Danso-Appiah A, Cronin de Chavez A Int J Health Policy Manag. 2024; 12:7994.

PMID: 38618785 PMC: 10699811. DOI: 10.34172/ijhpm.2023.7994.

References

Nguyen T, Knight R, Roughead E, Brooks G, Mant A . Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries. Health Policy Plan. 2014; 30(2):267-80. DOI: 10.1093/heapol/czt105. View

Senarathna S, Mannapperuma U, Fernandopulle B . Medicine prices, availability and affordability in Sri Lanka. Indian J Pharmacol. 2011; 43(1):60-3. PMC: 3062124. DOI: 10.4103/0253-7613.75672. View

Kasonde L, Tordrup D, Naheed A, Zeng W, Ahmed S, Babar Z . Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology. BMC Health Serv Res. 2019; 19(1):383. PMC: 6567665. DOI: 10.1186/s12913-019-4221-z. View

Wasir R, Irawati S, Makady A, Postma M, Goettsch W, Buskens E . Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia. PLoS One. 2019; 14(2):e0212328. PMC: 6380537. DOI: 10.1371/journal.pone.0212328. View

Kotwani A, Ewen M, Dey D, Iyer S, Lakshmi P, Patel A . Prices & availability of common medicines at six sites in India using a standard methodology. Indian J Med Res. 2007; 125(5):645-54. View

Saeed A, Saeed H, Saleem Z, Fang Y, Babar Z . Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology. PLoS One. 2019; 14(4):e0216122. PMC: 6483245. DOI: 10.1371/journal.pone.0216122. View

Babar Z, Ibrahim M, Singh H, Bukahri N, Creese A . Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007; 4(3):e82. PMC: 1831730. DOI: 10.1371/journal.pmed.0040082. View

Gustafsson L, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselstrom J . The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011; 108(4):224-33. DOI: 10.1111/j.1742-7843.2011.00682.x. View

Glerum P, Maliepaard M, de Valk V, Burger D, Neef K . Drug switching in the Netherlands: a cohort study of 20 active substances. BMC Health Serv Res. 2020; 20(1):650. PMC: 7359503. DOI: 10.1186/s12913-020-05494-x. View

10.

Eriksen J, Gustafsson L, Ateva K, Bastholm-Rahmner P, Ovesjo M, Jirlow M . High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open. 2017; 7(4):e014345. PMC: 5775463. DOI: 10.1136/bmjopen-2016-014345. View

11.

Saeed A, Saeed H, Saleem Z, Yang C, Jiang M, Zhao M . Impact of National Drug Pricing Policy 2018 on access to medicines in Lahore division, Pakistan: a pre-post survey study using WHO/HAI methodology. BMJ Open. 2020; 10(10):e034720. PMC: 7545625. DOI: 10.1136/bmjopen-2019-034720. View

12.

Lambojon K, Chang J, Saeed A, Hayat K, Li P, Jiang M . Prices, Availability and Affordability of Medicines with Value-Added Tax Exemption: A Cross-Sectional Survey in the Philippines. Int J Environ Res Public Health. 2020; 17(14). PMC: 7400398. DOI: 10.3390/ijerph17145242. View

13.

Vogler S, Paris V, Ferrario A, Wirtz V, de Joncheere K, Schneider P . How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Appl Health Econ Health Policy. 2017; 15(3):307-321. DOI: 10.1007/s40258-016-0300-z. View

14.

Babar Z, Scahill S . Is there a role for pharmacoeconomics in developing countries?. Pharmacoeconomics. 2010; 28(12):1069-74. DOI: 10.2165/11584890-000000000-00000. View